HDAC inhibitors are currently being developed as cancer therapeutics, mainly because of their ability to inhibit cancer cell growth in vitro and in vivo, to induce apoptosis, and to enhance cell differentiation [39], [40]. The gene discussed is HDAC9; the disease is cancer.